News Detail
NEW DELHI, 16 OCT 2024: The Indian Patent Office has rejected the grant of a patent for dolutegravir, a crucial HIV drug marketed by Viiv Healthcare, facilitating the entry of generics and expanding access to affordable, life-saving treatment. The decision, announced after a contentio......
View Details
View Details
Source : The Times of India
Today news
Google news
Breaking news
Viiv Healthcare
patent
Indian Patent Office
HIV drug
generics
evergreening
dolutegravir
Related News
- Police caught expired cosmetic goods in Meerut, DI denied action (09-11-2024)
- Sanitary napkins, baby diapers will now need BIS certification (09-11-2024)
- New Recruitment Rules for Medical Device Regulatory Positions (09-11-2024)
- Accused caught with 400 Pregabalin capsule handed over to DCO for further action (09-11-2024)
- Telangana DCA seize narcotic drugs, psychotropic substances from private hospitals (09-11-2024)
- Govt launches Rs 500 crore scheme to strengthen medical device industry (09-11-2024)
- Baddi firm asked to stop narcotic drug production amid CID probe (09-11-2024)
- Mohali police bust unit producing fake medicine (09-11-2024)
- Delhi HC restrains Aquakind labs from using 'AQUAKIND' trademark (09-11-2024)
- MBBS from abroad, started practicing medicine without passing FMGE, Registrations cancelled (08-11-2024)